EP1575510A4 - Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation - Google Patents
Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregationInfo
- Publication number
- EP1575510A4 EP1575510A4 EP03785053A EP03785053A EP1575510A4 EP 1575510 A4 EP1575510 A4 EP 1575510A4 EP 03785053 A EP03785053 A EP 03785053A EP 03785053 A EP03785053 A EP 03785053A EP 1575510 A4 EP1575510 A4 EP 1575510A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- aggregation
- compositions
- treatment
- methods
- exhibiting protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40219802P | 2002-08-07 | 2002-08-07 | |
US402198P | 2002-08-07 | ||
PCT/US2003/024868 WO2004014306A2 (en) | 2002-08-07 | 2003-08-07 | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1575510A2 EP1575510A2 (en) | 2005-09-21 |
EP1575510A4 true EP1575510A4 (en) | 2007-12-26 |
Family
ID=31715805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP03785053A Withdrawn EP1575510A4 (en) | 2002-08-07 | 2003-08-07 | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1575510A4 (en) |
JP (1) | JP2006509726A (en) |
KR (1) | KR20050053607A (en) |
CN (1) | CN101123993A (en) |
AU (1) | AU2003259073A1 (en) |
CA (1) | CA2494908A1 (en) |
IL (1) | IL166706A0 (en) |
NO (1) | NO20051159L (en) |
NZ (1) | NZ538145A (en) |
WO (1) | WO2004014306A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2007139120A1 (en) * | 2006-05-30 | 2009-10-08 | 国立大学法人大阪大学 | Amyloid β clearance promoter |
KR100982909B1 (en) * | 2009-07-08 | 2010-09-20 | 고려대학교 산학협력단 | Anti-cancer composition containing an ataxin-1 protein or a polynucleotide encoding ataxin-1 and a screening method of anti-cancer agents using the same |
WO2011015572A1 (en) * | 2009-08-03 | 2011-02-10 | Galapagos Nv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of neurodegenerative diseases |
WO2019032613A1 (en) * | 2017-08-08 | 2019-02-14 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of protein aggregation |
US20220411794A1 (en) | 2019-10-23 | 2022-12-29 | Universitaet Wien | Rna oligonucleotides for preventing aggregation of proteins |
WO2023205579A1 (en) * | 2022-04-18 | 2023-10-26 | The Regents Of The University Of California | Compositions and methods for disrupting pathological aggregates |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006545A2 (en) * | 1997-08-01 | 1999-02-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation |
WO1999029891A1 (en) * | 1997-12-09 | 1999-06-17 | Arch Development Corporation | Methods for identifying factors controlling amyloid protein aggregation |
WO2000073501A2 (en) * | 1999-06-01 | 2000-12-07 | LASMÉZAS, Corinne, Ida | Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof |
WO2001023412A2 (en) * | 1999-09-27 | 2001-04-05 | Massachusetts Institute Of Technology | Methods of screening for agents which inhibit aggregation of polypeptides |
WO2002054083A2 (en) * | 2001-01-03 | 2002-07-11 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
WO2002065136A2 (en) * | 2001-02-15 | 2002-08-22 | University Of Chicago | Yeast screens for agents affecting protein folding |
WO2003013437A2 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001575A1 (en) * | 1996-07-08 | 1998-01-15 | Pioneer Hi-Bred International, Inc. | Transformation of zygote, egg or sperm cells and recovery of transformed plants from isolated embryo sacs |
US20030060436A1 (en) * | 1998-11-05 | 2003-03-27 | Clifford Kent Weber Esq. | Treatment of parkinson's disease with oligonucleotides |
JPWO2003044197A1 (en) * | 2001-11-21 | 2005-03-24 | 独立行政法人科学技術振興機構 | Huntington's disease gene transcription factor |
US20030235823A1 (en) * | 2002-06-24 | 2003-12-25 | The University Of Alabama | Nucleotide sequences that code for torsin genes, torsin proteins, and methods of using the same to treat protein-aggregation |
-
2003
- 2003-08-07 KR KR1020057002251A patent/KR20050053607A/en not_active Application Discontinuation
- 2003-08-07 EP EP03785053A patent/EP1575510A4/en not_active Withdrawn
- 2003-08-07 CA CA002494908A patent/CA2494908A1/en not_active Abandoned
- 2003-08-07 NZ NZ538145A patent/NZ538145A/en unknown
- 2003-08-07 AU AU2003259073A patent/AU2003259073A1/en not_active Abandoned
- 2003-08-07 WO PCT/US2003/024868 patent/WO2004014306A2/en active Application Filing
- 2003-08-07 JP JP2004527888A patent/JP2006509726A/en active Pending
- 2003-08-07 CN CNA038238969A patent/CN101123993A/en active Pending
-
2005
- 2005-02-06 IL IL16670605A patent/IL166706A0/en unknown
- 2005-03-04 NO NO20051159A patent/NO20051159L/en not_active Application Discontinuation
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999006545A2 (en) * | 1997-08-01 | 1999-02-11 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Composition and method for the detection of diseases associated with amyloid-like fibril or protein aggregate formation |
WO1999029891A1 (en) * | 1997-12-09 | 1999-06-17 | Arch Development Corporation | Methods for identifying factors controlling amyloid protein aggregation |
WO2000073501A2 (en) * | 1999-06-01 | 2000-12-07 | LASMÉZAS, Corinne, Ida | Nucleic acid molecules with specific identification of native prpsc, their production and the use thereof |
WO2001023412A2 (en) * | 1999-09-27 | 2001-04-05 | Massachusetts Institute Of Technology | Methods of screening for agents which inhibit aggregation of polypeptides |
WO2002054083A2 (en) * | 2001-01-03 | 2002-07-11 | Ortho-Mcneil Pharmaceutical, Inc. | Alpha synuclein aggregation assays |
WO2002065136A2 (en) * | 2001-02-15 | 2002-08-22 | University Of Chicago | Yeast screens for agents affecting protein folding |
WO2003013437A2 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
Non-Patent Citations (4)
Title |
---|
CORDEIRO Y ET AL: "DNA converts cellular prion protein into the beta-sheet conformation and inhibits prion peptide aggregation", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOCHEMICAL BIOLOGISTS, BIRMINGHAM,, US, vol. 276, no. 52, 28 December 2001 (2001-12-28), pages 49400 - 49409, XP002196440, ISSN: 0021-9258 * |
KHOSHNAN ALI ET AL: "Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 99, no. 2, 22 January 2002 (2002-01-22), pages 1002 - 1007, XP002401586, ISSN: 0027-8424 * |
LECERF J-M ET AL: "Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 98, no. 8, 10 April 2001 (2001-04-10), pages 4764 - 4769, XP002323805, ISSN: 0027-8424 * |
PROSKE DANIELA ET AL: "Prion-protein-specific aptamer reduces PrPSc formation.", CHEMBIOCHEM : A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY. 2 AUG 2002, vol. 3, no. 8, 2 August 2002 (2002-08-02), pages 717 - 725, XP002401585, ISSN: 1439-4227 * |
Also Published As
Publication number | Publication date |
---|---|
NO20051159L (en) | 2005-04-26 |
CN101123993A (en) | 2008-02-13 |
EP1575510A2 (en) | 2005-09-21 |
NZ538145A (en) | 2008-05-30 |
AU2003259073A1 (en) | 2004-02-25 |
IL166706A0 (en) | 2006-01-15 |
KR20050053607A (en) | 2005-06-08 |
WO2004014306A3 (en) | 2006-05-18 |
JP2006509726A (en) | 2006-03-23 |
WO2004014306A2 (en) | 2004-02-19 |
CA2494908A1 (en) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1575480A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1578367A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1572116A4 (en) | Compositions and methods for the treatment of immune related diseases | |
EP1576137A4 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004024097A9 (en) | Compositions and methods for the treatment of immune related diseases | |
WO2004030615A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004016225A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1571968A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004045516A9 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1571968A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1560593A4 (en) | Novel composition and methods for the treatment of immune related diseases | |
EP1578421A4 (en) | Pharmaceutical preparations for treatments of diseases and disorders of the breast | |
AU2003268531A8 (en) | Materials and methods for treatment of allergic diseases | |
AU2003246102A8 (en) | Method of examining allergic disease and drug for treating the same | |
EP1572091A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1572091A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
WO2004060270A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
EP1553912A4 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
AU2003216592A8 (en) | Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases | |
HK1162127A1 (en) | Oil body associated protein compositions and methods as well as use thereof for reducing the risk of cardiovascular disease | |
WO2003057160A8 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
PL371281A1 (en) | Methods and compositions for the treatment of eye diseases | |
IL166706A0 (en) | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation | |
EP1578373A4 (en) | Novel compositions and methods for the treatment of immune related diseases | |
TWI347845B (en) | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20050224 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12Q 1/68 20060101ALI20060607BHEP Ipc: A61K 48/00 20060101AFI20060607BHEP |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070606 |
|
DA4 | Supplementary search report drawn up and despatched (deleted) | ||
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20071127 |
|
17Q | First examination report despatched |
Effective date: 20080625 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20110301 |